New targets for clinical trials in Europe
Submitted by Anonymous (not verified) on 23 September 2025 - 11:55
New targets for clinical trials in Europe
Use of paracetamol during pregnancy unchanged in the EU
Submitted by Anonymous (not verified) on 23 September 2025 - 11:15
Use of paracetamol during pregnancy unchanged in the EU
MedDRA important medical event terms list - version 28.1
Submitted by Anonymous (not verified) on 23 September 2025 - 10:14
MedDRA important medical event terms list - version 28.1
Training session on human variations web-based electronic application form (eAF) for CAPs, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 15 September 2025, 10:00 (CEST) to 15 September 2025, 11:30 (CEST)
Submitted by Anonymous (not verified) on 22 September 2025 - 14:16
Training session on human variations web-based electronic application form (eAF) for CAPs, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 15 September 2025, 10:00 (CEST) to 15 September 2025, 11:30 (CEST)
New variations guidelines to streamline lifecycle management of medicines
Submitted by Anonymous (not verified) on 22 September 2025 - 13:07
New variations guidelines to streamline lifecycle management of medicines
Guidance on the application of the revised variations framework
Submitted by Anonymous (not verified) on 22 September 2025 - 13:02
Guidance on the application of the revised variations framework
Agenda of the HMPC meeting 22-24 September 2025
Submitted by Anonymous (not verified) on 22 September 2025 - 12:39
Agenda of the HMPC meeting 22-24 September 2025
Human medicines European public assessment report (EPAR): Romvimza, vimseltinib, Date of authorisation: 17/09/2025, Status: Authorised
Submitted by Anonymous (not verified) on 22 September 2025 - 12:00
Human medicines European public assessment report (EPAR): Romvimza, vimseltinib, Date of authorisation: 17/09/2025, Status: Authorised
Human medicines European public assessment report (EPAR): Pyzchiva, ustekinumab, Date of authorisation: 19/04/2024, Revision: 11, Status: Authorised
Submitted by Anonymous (not verified) on 22 September 2025 - 11:20
Human medicines European public assessment report (EPAR): Pyzchiva, ustekinumab, Date of authorisation: 19/04/2024, Revision: 11, Status: Authorised
Human medicines European public assessment report (EPAR): Jayempi, azathioprine, Date of authorisation: 21/06/2021, Revision: 8, Status: Authorised
Submitted by Anonymous (not verified) on 22 September 2025 - 11:16
Human medicines European public assessment report (EPAR): Jayempi, azathioprine, Date of authorisation: 21/06/2021, Revision: 8, Status: Authorised